γ‑Klotho is correlated with resistance to docetaxel in castration‑resistant prostate cancer

Onishi,Kenta; Miyake,Makito; Hori,Shunta; Onishi,Sayuri; Iida,Kota; Morizawa,Yosuke; Tatsumi,Yoshihiro; Nakai,Yasushi; Tanaka,Nobumichi; Fujimoto,Kiyohide

doi:10.3892/ol.2020.11308

γ‑Klotho is correlated with resistance to docetaxel in castration‑resistant prostate cancer

Authors:
- Kenta Onishi
- Makito Miyake
- Shunta Hori
- Sayuri Onishi
- Kota Iida
- Yosuke Morizawa
- Yoshihiro Tatsumi
- Yasushi Nakai
- Nobumichi Tanaka
- Kiyohide Fujimoto
View Affiliations

Affiliations: Department of Urology, Nara Medical University, Kashihara, Nara 634‑8521, Japan
Published online on: January 16, 2020 https://doi.org/10.3892/ol.2020.11308
Pages: 2306-2316
Copyright: © Onishi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The Klotho (KL) gene was first identified as a potent aging suppressor. The KL family currently comprises of three proteins: α‑Klotho (KLA), β‑Klotho (KLB), and γ‑Klotho (KLG). Many studies have shown that KLA and KLB participate in tumor progression or suppression, depending on the type of cancer; however, the relationship between KLG and prostate cancer has not yet been studied. Some studies have claimed that KL is correlated to sensitivity to chemotherapy. Here, we investigated the oncogenic potential of KLG in castration‑resistant prostate cancer (CRPC). Immunohistochemical analysis using prostate biopsy specimens revealed that patients with high KLG expression in primary prostate cancer tissue had a significantly poor prognosis for overall survival. In addition, the prostate‑specific antigen response rate after docetaxel (DTX) therapy in patients with high KLG expression was lower than that in patients with low KLG expression. To evaluate the potential of KLG as a therapeutic target in human prostate cancer, we generated a xenograft model of human CRPC cell line (PC‑3) in male athymic mice. The animals were randomly divided into four groups as follows: i) control group (vehicle only); ii) DTX group (intraperitoneal administration); iii) small interfering RNA targeting KLG (KLG siRNA) group (intratumoral administration); and iv) a combination group (DTX plus KLG siRNA). After 3 weeks of treatment, the tumor weight and tumor Ki‑67 labeling index were significantly lower in the KLG siRNA group and the combination group than in the control group. Sensitivity to DTX was increased upon treatment with KLG siRNA. These findings suggest that KLG expression in primary prostate cancer lesions is associated with resistance to DTX in CRPC and has potential as a diagnostic and therapeutic target for patients with CRPC.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Lowrance WT, Roth BJ, Kirkby E, Murad MH and Cookson MS: Castration-resistant prostate cancer: AUA guideline amendment 2015. J Urol. 195:1444–1452. 2016. View Article : Google Scholar : PubMed/NCBI
3	Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 351:1502–1512. 2004. View Article : Google Scholar : PubMed/NCBI
4	Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 351:1513–1520. 2004. View Article : Google Scholar : PubMed/NCBI
5	Carroll PR, Parsons JK, Andriole G, Bahnson RR, Castle EP, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, et al: NCCN guidelines insights: Prostate cancer early detection, version 2.2016. J Natl Compr Canc Netw. 14:509–519. 2016. View Article : Google Scholar : PubMed/NCBI
6	Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, et al: Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 390:45–51. 1997. View Article : Google Scholar : PubMed/NCBI
7	Ito S, Fujimori T, Hayashizaki Y and Nabeshima Y: Identification of a novel mouse membrane-bound family 1 glycosidase-like protein, which carries an atypical active site structure. Biochim Biophys Acta. 1576:341–345. 2002. View Article : Google Scholar : PubMed/NCBI
8	Kurosu H and Kuro-O M: The Klotho gene family as a regulator of endocrine fibroblast growth factors. Mol Cell Endocrinol. 299:72–78. 2009. View Article : Google Scholar : PubMed/NCBI
9	Kim J, Eskiocak U, Stadler G, Lou Z, Kuro-o M, Shay JW and Wright WE: Short hairpin RNA screen indicates that Klotho beta/FGF19 protein overcomes stasis in human colonic epithelial cells. J Biol Chem. 286:43294–43300. 2011. View Article : Google Scholar : PubMed/NCBI
10	Tiong KH, Mah LY and Leong CO: Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers. Apoptosis. 18:1447–1468. 2013. View Article : Google Scholar : PubMed/NCBI
11	Schlessinger J: Common and distinct elements in cellular signaling via EGF and FGF receptors. Science. 306:1506–1507. 2004. View Article : Google Scholar : PubMed/NCBI
12	Miyake M, Ishii M, Koyama N, Kawashima K, Kodama T, Anai S, Fujimoto K, Hirao Y and Sugano K: 1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido [2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27/Kip1 and G1/G0 arrest. J Pharmacol Exp Ther. 332:795–802. 2010. View Article : Google Scholar : PubMed/NCBI
13	Zhou X and Wang X: Klotho: A novel biomarker for cancer. J Cancer Res Clin Oncol. 141:961–969. 2015. View Article : Google Scholar : PubMed/NCBI
14	Wolf I, Levanon-Cohen S, Bose S, Ligumsky H, Sredni B, Kanety H, Kuro-o M, Karlan B, Kaufman B, Koeffler HP and Rubinek T: Klotho: A tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer. Oncogene. 27:7094–7105. 2008. View Article : Google Scholar : PubMed/NCBI
15	Chen B, Wang X, Zhao W and Wu J: Klotho inhibits growth and promotes apoptosis in human lung cancer cell line A549. J Exp Clin Cancer Res. 29:992010. View Article : Google Scholar : PubMed/NCBI
16	Doi S, Zou Y, Togao O, Pastor JV, John GB, Wang L, Shiizaki K, Gotschall R, Schiavi S, Yorioka N, et al: Klotho inhibits transforming growth factor-beta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J Biol Chem. 286:8655–8665. 2011. View Article : Google Scholar : PubMed/NCBI
17	Zhu Y, Xu L, Zhang J, Xu W, Liu Y, Yin H, Lv T, An H, Liu L, He H, et al: Klotho suppresses tumor progression via inhibiting PI3K/Akt/GSK3β/Snail signaling in renal cell carcinoma. Cancer Sci. 104:663–671. 2013. View Article : Google Scholar : PubMed/NCBI
18	Xie B, Zhou J, Yuan L, Ren F, Liu DC, Li Q and Shu G: Epigenetic silencing of Klotho expression correlates with poor prognosis of human hepatocellular carcinoma. Hum Pathol. 44:795–801. 2013. View Article : Google Scholar : PubMed/NCBI
19	Poh W, Wong W, Ong H, Aung MO, Lim SG, Chua BT and Ho HK: Klotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinoma. Mol Cancer. 11:142012. View Article : Google Scholar : PubMed/NCBI
20	Feng S, Dakhova O, Creighton CJ and Ittmann M: Endocrine fibroblast growth factor FGF19 promotes prostate cancer progression. Cancer Res. 73:2551–2562. 2013. View Article : Google Scholar : PubMed/NCBI
21	Ye X, Guo Y, Zhang Q, Chen W, Hua X, Liu W, Yang Y and Chen G: bKlotho suppresses tumor growth in hepatocellular carcinoma by regulating Akt/GSK-3β/cyclin D1 signaling pathway. PLoS One. 8:e556152013. View Article : Google Scholar : PubMed/NCBI
22	Hori S, Miyake M, Onishi S, Tatsumi Y, Morizawa Y, Nakai Y, Anai S, Tanaka N and Fujimoto K: Clinical significance of α- and β-Klotho in urothelial carcinoma of the bladder. Oncol Rep. 36:2117–2125. 2016. View Article : Google Scholar : PubMed/NCBI
23	Hori S, Miyake M, Tatsumi Y, Morizawa Y, Nakai Y, Onishi S, Onishi K, Iida K, Gotoh D, Tanaka N and Fujimoto K: Gamma-Klotho exhibits multiple roles in tumor growth of human bladder cancer. Oncotarget. 9:19508–19524. 2018. View Article : Google Scholar : PubMed/NCBI
24	Trošt N, Peña-Llopis S, Koirala S, Stojan J, Potts PR, Fon Tacer K and Martinez ED: γKlotho is a novel marker and cell survival factor in a subset of triple negative breast cancers. Oncotarget. 7:2611–2628. 2016. View Article : Google Scholar : PubMed/NCBI
25	Abramovitz L, Rubinek T, Ligumsky H, Bose S, Barshack I, Avivi C, Kaufman B and Wolf I: KL1 internal repeat mediates klotho tumor suppressor activities and inhibits bFGF and IGF-I signaling in pancreatic cancer. Clin Cancer Res. 17:4254–4266. 2011. View Article : Google Scholar : PubMed/NCBI
26	Fon Tacer K, Bookout AL, Ding X, Kurosu H, John GB, Wang L, Goetz R, Mohammadi M, Kuro-o M, Mangelsdorf DJ and Kliewer SA: Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol. 24:2050–2064. 2010. View Article : Google Scholar : PubMed/NCBI
27	Nagamatsu H, Teishima J, Goto K, Shikuma H, Kitano H, Shoji K, Inoue S and Matsubara A: FGF19 promotes progression of prostate cancer. Prostate. 75:1092–1101. 2015. View Article : Google Scholar : PubMed/NCBI
28	Anai S, Goodison S, Shiverick K, Hirao Y, Brown BD and Rosser CJ: Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenografts. Mol Cancer Ther. 6:101–111. 2007. View Article : Google Scholar : PubMed/NCBI
29	Ito T, Shimada Y, Kan T, David S, Cheng Y, Mori Y, Agarwal R, Paun B, Jin Z, Olaru A, et al: Pituitary tumor-transforming 1 increases cell motility and promotes lymph node metastasis in esophageal squamous cell carcinoma. Cancer Res. 68:3214–3224. 2008. View Article : Google Scholar : PubMed/NCBI
30	Li LT, Jiang G, Chen Q and Zheng JN: Ki67 is a promising molecular target in the diagnosis of cancer (Review). Mol Med Rep. 11:1566–1572. 2015. View Article : Google Scholar : PubMed/NCBI
31	Wang Y, Chen L, Huang G, He D, He J, Xu W, Zou C, Zong F, Li Y, Chen B, et al: Klotho sensitizes human lung cancer cell line to cisplatin via PI3k/Akt pathway. PLoS One. 8:e573912013. View Article : Google Scholar : PubMed/NCBI
32	Gao L, Wang X, Tang Y, Huang S, Hu CA and Teng Y: FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib. J Exp Clin Cancer Res. 36:82017. View Article : Google Scholar : PubMed/NCBI
33	Cao J, Zhu X, Zhao X, Li XF and Xu R: Neutrophil-to-lymphocyte ratio predicts PSA response and prognosis in prostate cancer: A systematic review and meta-analysis. PLoS One. 11:e01587702016. View Article : Google Scholar : PubMed/NCBI